GeneCentric is a proud sponsor of the 8th Annual MarketsandMarkets Biomarker & Companion Diagnostics Conference to be held February 8-9, 2023 in San Diego, CA. Experts from academia and industry will present new information on cancer biomarker validation for clinical applications, biomarkers and personalized medicine, the impact of big data in translational biomarker research, the future of companion diagnostics, and the latest updates on regulatory guidelines and approvals. Learn more and register here.
Mike Milburn, PhD | GeneCentric President & CEO
Topic: The Future of RNA Diagnostics in Cancer
- While DNA mutation and alteration status is an important biomarker for cancer therapies, newRNA expression tests offer several key advantages for companion diagnostics
- The explosive growth of RNA whole transcriptome clinical assays can be used to power new and more informative gene expression tests
- Adoption of RNA expression tests as companion diagnostics will require close collaboration with drug developers and diagnostic clinical utility studies